A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials

Dawood H Sultan; Diana G Ghebrezadik; Desiree S Smith; David N Ombengi; Lolade Ayedun; Faith E Luke; Janee L Demery; Chris T Scoggins; Michelle Penn-Marshall

doi:10.1007/s40615-023-01737-9

A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials

J Racial Ethn Health Disparities. 2023 Aug 8. doi: 10.1007/s40615-023-01737-9. Online ahead of print.

Authors

Dawood H Sultan¹, Diana G Ghebrezadik², Desiree S Smith², David N Ombengi³, Lolade Ayedun⁴, Faith E Luke², Janee L Demery², Chris T Scoggins², Michelle Penn-Marshall⁵

Affiliations

¹ Mercer University, College of Health Professions, Atlanta, GA, USA. sultan.nuba@gmail.com.
² Mercer University, College of Health Professions, Atlanta, GA, USA.
³ South University, School of Pharmacy, Savannah, GA, USA.
⁴ Mercer University, College of Pharmacy, Atlanta, GA, USA.
⁵ Texas Southern University, Houston, TX, USA.

PMID: 37552424
DOI: 10.1007/s40615-023-01737-9

Abstract

Background: Obesity, diagnosed in 41.1% of African American (AA) men, is a risk factor for prostate cancer (PCa) recurrence, progression, and increased mortality. Obesity is associated with aggressive PCa only in AA men and not White American (WA) men. The overall health of AA PCa patients is also more likely to be adversely affected by comorbid type 2 diabetes (T2D), often an outcome of obesity and a cause of reduced odds of PCa survival. This evidence suggests that preventing and controlling comorbid obesity and T2D in AA men diagnosed with PCa should be a research funding priority.

Aim: The aim of this study is to determine if federally funded PCa clinical trials controlled T2D and obesity.

Methods: Completed interventional PCa clinical trials conducted in the USA, funded by the NIH or other federal agency, which included males aged 18-64 years, and reported study protocols were included in the study. We examined the intervention modalities used in the trials to determine if any attempted to control obesity and T2D.

Results: Fifty-eight trials met the study inclusion criteria. Of these 11 were excluded from the analysis as they did not report AA men. A total of 5802 men participated in the remaining 47 trials. Of these, 917 (15.8%) were AA and 4885 (84.2%) were WA men. Forty (85.1%) trials used pharmaceutical medication therapies or other clinical procedures. None of the medications or clinical procedures used were indicated for treatment of obesity and T2D. 5 (10.6%) trials addressed treatment preferences, survivorship, coping, function, and incontinence among PCa patients. Only 2 (4.25%) trials examined weight loss and diet.

Conclusions: None of the completed federally funded PCa clinical trials that included AA men used methods to control T2D. Only an insignificant number (4.25%) attempted to control obesity. This gap in therapeutic optimization to control these comorbid conditions indicates a critical area in need of federal funding priority.

Keywords: African American men; Clinical trials; Diabetes; NIH; Obesity; Prostate cancer.